Expert Review of Hematology
ISSN:1747-4086

Expert Review of Hematology

EXPERT REV HEMATOL
学科领域:医学
是否预警:不在预警名单内
是否OA:
录用周期:较慢,6-12周
新锐分区:医学4区
年发文量:91
影响因子:2.1
JCR分区:Q3

基本信息

近年来,先进的分子研究技术已经改变了血液学。随着对血液病认识的提高,我们现在有机会研究和评估新的生物疗法、新的药物和药物组合、新的治疗方案和新的方法,包括干细胞移植。我们还可以期待蛋白质组学、分子遗传学和生物标志物研究促进新的诊断方法和适当疗法的确定。我们对血细胞和造血组织的形成和功能的认识将继续取得进一步的进展,对血液学家来说,采用这些新的范式并制定综合策略来定义最佳的患者护理将是一个重大挑战。《血液学专家评论》(1747-4086)将这些进展置于背景中,并探讨了它们将如何直接转化为临床实践。
1747-4086SCIE/Scopus收录
2.1
2.9
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学4区
HEMATOLOGY 血液学
4区
N/A
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科:HEMATOLOGY
SCIE
Q3
55/99
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科:HEMATOLOGY
SCIE
Q3
59/100
31
91
3%0较慢,6-12周-HEMATOLOGY-
0%
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
37.36%7.8%0.92%
CiteScore:4.30
SJR:0.724
SNIP:0.674
学科类别分区排名百分位
大类:Medicine
小类:Hematology
Q2
59 / 142

期刊高被引文献

High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1636645
An update on the biology and management of dyskeratosis congenita and related telomere biology disorders
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1662720
CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1649132
Platelet function assays in diagnosis: an update
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1562333
Overcoming challenges of venous thromboembolism in sickle cell disease treatment
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1583554
Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1562331
Considering the spleen in sickle cell disease
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1627192
A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1605288
Risk factors, management and prevention of transfusion-related acute lung injury: a comprehensive update
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1640599
The role of regulatory T cells in graft-versus-host disease management
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2020.1709436
Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1575130
The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1617129
Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromes
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1645004
What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1593824
Humanistic burden of patients with chronic graft-versus-host disease - systematic literature review of health-related quality of life and functional status
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1602036
Novel therapies in low- and high-risk myelodysplastic syndrome
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1647778
Quality of life in multiple myeloma: considerations and recommendations
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1613886
Management of antithrombin deficiency: an update for clinicians
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1611424
Switching patients in the age of long-acting recombinant products?
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2018.1564032
Management of aplastic anemia after failure of frontline immunosuppression
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1645003
An update on: molecular genetics of high-risk chronic lymphocytic leukemia
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2020.1697225
Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1596793
Therapeutic potential of PI3K signaling in distinct entities of B-cell lymphoma
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1676716
Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1560259
Current and emerging treatments for immune thrombocytopenia
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1636644
Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1652590
Developments in the use of plasma exchange and adjunctive therapies to treat immune-mediated thrombotic thrombocytopenic purpura
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1619170
Emicizumab for hemophilia A without inhibitors
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1624519
Contemporary management of essential thrombocythemia in children
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1602034
Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1660640
Improving fibrinolysis in venous thromboembolism: impact of fibrin structure
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1627193
Timing treatment for smoldering myeloma: is earlier better?
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1599281
Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1643232
Clinical impact of the cell-of-origin classification based on immunohistochemistry criteria and Lymph2Cx of diffuse large B-Cell lymphoma patients in a South-east Asian population: a single center experience and review of the literature
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1677152
Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1643231
When to use stem cell transplant in mantle cell lymphoma
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1588106
Time for patient reported outcomes assessment in routine hematology practice: the case of chronic myeloid leukemia
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1547189
Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1645002
Tranexamic acid for childbirth: why, when, and for whom
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1642744
Umbilical cord blood transplantation and the impact of the CTLA4 genotype on outcomes
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1680281
BRAF in the cross-hairs
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1583553
Histological transformation in malignant lymphoma: a possible role of PET/CT and circulating tumor DNA as noninvasive diagnostic tools
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2020.1690987
An update on treatment of higher risk myelodysplastic syndromes
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2018.1537777
What are the implications of cost for myeloma therapy?
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1682545
An alternative way – tyrosine kinase inhibitor (TKI) de-escalation – to discontinue TKIs in order to achieve treatment-free remission
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1623666
An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1658522
Current perspectives on the treatment of double hit lymphoma
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1623020
Blinatumomab: a novel therapy for the treatment of non-Hodgkin’s lymphoma
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1676717
Myelofibrosis: best practices, controversies and 2019 update
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2020.1691519
Unraveling innovation potential in the real-world setting: eighteen novel agents with twenty-six approved European indications, in the management of leukemias, lymphomas, and multiple myeloma
来源期刊:Expert Review of HematologyDOI:10.1080/17474086.2019.1668763

相关文章

2026年3月发布
大类学科小类学科Top期刊综述期刊
医学4区
HEMATOLOGY 血液学
4区
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学4区
HEMATOLOGY 血液学
4区
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学4区
HEMATOLOGY 血液学
4区